Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study

View Full Paper
Ask AI
Bookmark
Share

Authors

STSabrin TahriGAGloria AguilarMDMargaret Doyle

Discussion

Loading...

Member takes

Overview

Phase II trial shows efficacy and safety of daratumumab with teclistamab and talquetamab in frail multiple myeloma patients, suggesting treatment-free intervals are promising.

Key Points

  • This trial aims to evaluate the efficacy and safety of fixed-duration combinations of bispecific antibodies in frail patients with newly diagnosed multiple myeloma.
  • Phase II multicenter study with two cohorts: Tec-Dara and Tal-Dara.
  • 150 frail NDMM patients enrolled based on International Myeloma Working Group Frailty Index.
  • Primary outcome: progression-free survival at 18 months; safety evaluated alongside efficacy.
  • Daratumumab combined with teclistamab or talquetamab may enhance treatment efficacy in frail patients.
  • Treatment-free intervals suggested to be feasible, with potential for better tolerability.

Cite This Study

Tahri et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daa2https://doi.org/10.1182/blood-2025-4064
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a2025 · 12 citations
  2. 2A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)2025
  3. 3MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.2022 · 19 citations
  4. 4Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study2025 · 20 citations
  5. 5Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis2025